The independent source for health policy research, polling, and news.
561 - 580 of 1,289 Results
Everyone — from toilet paper manufacturers to patient advocates — is lobbying state advisory boards, arguing their members are essential, vulnerable or both — and, thus, most deserving of an early vaccine.
With two vaccines against coronavirus disease poised for release within weeks, experts say they expect attitudes to shift dramatically from hesitancy to “Beanie Baby”-level urgency.
Fears over COVID-19 have contributed to a slump in inoculations among children. Now the federal government is looking to pharmacists for help, but many of them do not participate in a program that offers free shots to half the kids in the U.S.
COVID-19’s “long haulers” — patients with lingering effects of the disease — have joined the ranks of Americans with preexisting conditions. For those shopping for health coverage on the individual market, here’s help navigating an uncharted insurance landscape.
Widespread COVID testing has revealed uncomfortable truths about medical tests: A test result is rarely a definitive answer, but instead a single clue. A result may be falsely positive or negative, or it may show an abnormality that doesn’t matter. And as COVID testing has made too clear, even an accurate, meaningful result is useless unless it’s acted on appropriately.
A Trump administration maneuver allows executives who are leading the federal effort to keep investments in drug companies that would benefit from the pandemic response.
A proposal in Washington state would use right-to-try laws to allow terminally ill patients access to psilocybin — the famed magic mushrooms of America’s psychedelic ’60s — to ease depression and anxiety.
A provision the Trump administration tucked into its final rule on health plan price transparency requires telling consumers what they will pay out-of-pocket for drugs and showing them what the plan paid.
Drugmakers will walk away with massive profits, but much of the pioneering work on mRNA vaccines was done with government money.
The tax was touted as a way to generate funding for treatment programs across the state. But to avoid paying, scores of manufacturers and wholesalers stopped selling opioids in New York.
From the likelihood of achy, flu-like side effects to the need for two doses, weeks apart, consumers need to know now what to expect when vaccines to prevent COVID-19 roll out.
The drugmaker says its mRNA vaccine worked in 90% of patients in its trial, but some observers question how long immunity will last and who will benefit.
Human clinical trials are scheduled for a drug that could prevent some of the 100,000-plus deaths from snakebites worldwide each year. The same drug may also help people suffering from COVID-related acute respiratory distress.
The Department of Veterans Affairs hopes to enroll 8,000 people in advanced-stage trials of four leading vaccine candidates. The Defense Department earlier announced plans to enlist 3,000 volunteers in trials.
President Donald Trump wants to send seniors $200 apiece. Beyond the legal and logistical problems, health care experts point out it does little to help someone with even typical prescription costs.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Some argue that vaccines capable of preventing any COVID-19 symptoms should qualify for widespread use, but others want much larger trials to prove the vaccines can reduce hospitalizations or deaths.
No private firms bid on the $30 million contract to set up and operate the state’s plan to bring in cheaper drugs. The setback is likely to delay by at least several months Florida’s effort to become the first state to import drugs under new federal regulations.
The progressive Change Now PAC launched a campaign ad, which also circulated on Facebook, criticizing President Donald Trump and Sen. Thom Tillis (R-N.C.) for not “fighting” for people with diabetes who struggle with the high cost of insulin.
President Donald Trump has been heralding drugmakers as “great companies.” Yet in the final stretch of the presidential campaign, Trump is not feeling the love in pharma contributions. Former Vice President Joe Biden is, even though his proposed policies could dent the industry’s profitability.
© 2026 KFF